Stock Events

Stock Events

Inhibikase Therapeutics 

$2.39
23
-$0.07-2.65% 16:01 Today

Statistics

Day High
2.4
Day Low
2.37
52W High
2.53
52W Low
1.33
Volume
1,125
Avg. Volume
-
Mkt Cap
332.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.15
0.19
0.54
0.88
Expected EPS
-0.11375
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-48.26MNet Income

Analyst Ratings

4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IKT. It's not an investment recommendation.
Apple
4
AAPL
Realty Income
4
O
Tesla
4
TSLA
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen has a strong portfolio in neurodegenerative diseases, directly competing with Inhibikase's Parkinson's and related disorders treatments.
Palatin Technologies
PTN
Mkt Cap16.65M
Palatin Technologies works on treatments for diseases with a focus on inflammatory and central nervous system diseases, overlapping with Inhibikase's therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
Acadia Pharmaceuticals specializes in central nervous system disorders, including Parkinson’s disease psychosis, directly competing with Inhibikase.
Alkermes
ALKS
Mkt Cap8.23B
Alkermes focuses on central nervous system diseases, including treatments for neurological disorders, competing in the same therapeutic area as Inhibikase.
AMGEN
AMGN
Mkt Cap224.63B
Amgen has a broad focus on biologics in various therapeutic areas, including neurology, potentially competing with Inhibikase's pipeline.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a strong presence in neuroscience, including Parkinson's disease treatments, making it a direct competitor to Inhibikase.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a diverse portfolio that includes treatments for neurological disorders, potentially competing with Inhibikase's focus areas.
Novartis
NVS
Mkt Cap286.78B
Novartis offers treatments for a wide range of health conditions, including neurological diseases, competing with Inhibikase's research and development focus.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad research portfolio that includes neuroscience, potentially putting it in competition with Inhibikase for market share in neurodegenerative disease treatments.

About

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Show more...
CEO
Mark T. Iwicki
Employees
35
Country
United States
ISIN
US45719W2052
WKN
000A2QAMK

Listings

MU
DE
IQT.MU
STU
DE
IQT0.STU
MU
DE
IQT0.MU
STU
DE
IQT.STU

0 Comments

Share your thoughts

FAQ

What is Inhibikase Therapeutics stock price today?▼
The current price of IKT is $2.39 USD — it has decreased by -2.65% in the past 24 hours. Watch Inhibikase Therapeutics stock price performance more closely on the chart.
What is Inhibikase Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Inhibikase Therapeutics stocks are traded under the ticker IKT.
Is Inhibikase Therapeutics stock price growing?▼
IKT stock has fallen by -1.24% compared to the previous week, the month change is a +6.73% rise, over the last year Inhibikase Therapeutics has showed a +41.67% increase.
What is Inhibikase Therapeutics market cap?▼
Today Inhibikase Therapeutics has the market capitalization of 332.79M
When is the next Inhibikase Therapeutics earnings date?▼
Inhibikase Therapeutics is going to release the next earnings report on November 16, 2026.
What were Inhibikase Therapeutics earnings last quarter?▼
IKT earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.11 USD resulting in a -2.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inhibikase Therapeutics revenue for the last year?▼
Inhibikase Therapeutics revenue for the last year amounts to 0 USD.
What is Inhibikase Therapeutics net income for the last year?▼
IKT net income for the last year is -48.26M USD.
How many employees does Inhibikase Therapeutics have?▼
As of August 20, 2026, the company has 35 employees.
In which sector is Inhibikase Therapeutics located?▼
Inhibikase Therapeutics operates in the Health & Wellness sector.
When did Inhibikase Therapeutics complete a stock split?▼
The last stock split for Inhibikase Therapeutics was on June 30, 2023 with a ratio of 1:6.
Where is Inhibikase Therapeutics headquartered?▼
Inhibikase Therapeutics is headquartered in WILMINGTON, United States.